Диссертация (1140116), страница 40
Текст из файла (страница 40)
Williamson[et al.] // Archives of internal medicine. – 2009. – Vol. 169, N 13. – P. 1195-1202.340. Central angiotensin II stimulation promotes beta amyloid production in Sprague Dawley rats /D. Zhu, J. Shi, Y. Zhang [et al.] // PLoS One. – 2011. – Vol. 6, N 1. – P. e16037.341.
Moncada, S. Nitric oxide: physiology, pathophysiology and pharmacology // S. Moncada, R.M.Palmer, E.A. Higgs // Pharmacological Reviews. – 1991. – Vol. 43, N 2. – P. 109–142.342. Duron, E. Antihypertensive treatments, cognitive decline, and dementia / E. Duron, O. Hanon //Journal of Alzheimer's Disease. – 2010. – Vol. 20, N 3. – P. 903-914.343. Pieniaże, W. Comparison of the effect of perindopril and acebutolol on cerebralhemodynamics in hypertensive patients / W. Pieniaże, P. P. Dimitrow, T. Jasiński //Cardiovascular Drugs and Therapy.
- 2001. – Vol. 15, N 1. – P. 63–67.344. Inhibition of central angiotensin converting enzyme ameliorates scopolamine induced memoryimpairment in mice: Role of cholinergic neurotransmission, cerebral blood flow and brain energymetabolism / S. Tota, C. Nath, A. K. Najmi [et al.] // Behavioural Brain Research. – 2012. – Vol.232, N 1.
– P. 66-76.345. Antihypertensive drug use and the risk of dementia in patients with diabetes mellitus / M.L.Johnson, N. Parikh, M.E. Kunik [et al.] // Alzheimer's & Dementia. – 2012. – Vol. 8, N 5. – P.437–444.346. Wu, C.L. A 10-year follow-up study of the association between calcium channel blocker useand the risk of dementia in elderly hypertensive patients / C.L. Wu, S.H. Wen // Medicine(Baltimore).
– 2016. – Vol. 95, N 32. – P. e4593.347. Calcium channel blocker use reduces incident dementia risk in elderly hypertensive patients: Ameta-analysis of prospective studies / S. Hussain, A. Singh, S.O. Rahman [et al.] // NeuroscienceLetters. – 2018. – Vol. 671. – P.
120–127.168348. Gorelick, P.B. Blood pressure and treatment of persons with hypertension as it relates tocognitive outcomes including executive function / P.B. Gorelick, D. Nyenhuis // Journal of theAmerican Society of Hypertension. – 2012. – Vol. 6, N 5. – P. 309–315.349. Toescu, E.C.
Metabolic substrates of neuronal aging / E.C. Toescu, J. Xiong // Annals of theNew York Academy of Sciences. – 2004. – Vol. 1019. – P. 19–23.350. Use of calcium antagonists and cognitive decline in old age. The Leiden 85-plus study / S.Trompet, R.G. Westendorp, A.M. Kamper [et al.] // Neurobiology of Aging. – 2008. – Vol. 29, N2. – P. 306–308.351. Возможности амлодипина в терапии артериальной гипертонии / В.М. Царева, Н.Ю.Хозяинова, М.С.
Безалтынных [и др.] // Рациональная фармакотерапия в кардиологии2008ю – Т. 4, № 5. – С. 53–56.352. Berridge, M.J. Calcium signalling and Alzheimer’s disease / M.J. Berridge // NeurochemicalResearch. – 2011. – Vol. 36, N 7. – P. 1149–1156.353. Thibault, O. Increase in single L-type calcium channels in hippocampal neurons during aging /O. Thibault, P.W. Landfield // Science. – 1996. – Vol.
272, N 5264. – P. 1017–1020.354. Thibault, O. Expansion of the calcium hypothesis of brain aging and Alzheimer’s disease:minding the store / O. Thibault, J.C. Gant, P.W. Landfield // Aging Cell. – 2007. – Vol. 6, N 3. –P. 307–317.355.
Intraneuronal amyloid-beta1-42 production triggered by sustained increase of cytosolic calciumconcentration induces neuronal death // N. Pierrot, P. Ghisdal, A.-S. Caumont [et al.] // Journal ofNeurochemistry. – 2004. – Vol. 88, N 5. – P. 1140–1150.356. Querfurth, H.W. Calcium ionophore increases amyloid beta peptide production by culturedcells / H.W. Querfurth, D.J. Selkoe // Biochemistry (Moscow).
– 1994. - Vol. 33, N 15. – P.4550–4561.357. Mattson, M.P. Antigenic changes similar to those seen in neurofibrillary tangles are elicited byglutamate and Ca2+ influx in cultured hippocampal neurons / M.P. Mattson // Neuron. - 1990. –Vol. 4, N 1. – P. 105–117.358. Villapol, S. Neuroprotective effects of angiotensin receptor blockers / S. Villapol, J.M.Saavedra // American Journal of Hypertension. – 2015. – Vol. 28, N 3. – P. 289-299.359. Brain penetration of telmisartan, a unique centrally acting angiotensin II type 1 receptorblocker, studied by PET in conscious rhesus macaques / A.
Noda, H. Fushiki, Y. Murakami [etal.] // Nuclear Medicine and Biology. – 2012. – Vol. 39. – P. 1232–1235.360. Whole-body distribution and radiation dosimetry of [11C]telmisartan as a biomarker forhepatic organic anion transporting polypeptide (OATP) 1B3 / K. Shimizu, T. Takashima, T.Yamane [et al.] // Nuclear Medicine and Biology. – 2012. – Vol. 39. – P.
847–853.169361. Angiotensin II AT1 receptor blockade ameliorates brain inflammation / J. Benicky, E. SánchezLemus, M. Honda [et al.] // Neuropsychopharmacology. – 2011. – Vol. 36. – P. 857–870.362. Anti-inflammatory effects of angiotensin receptor blockers in the brain and the periphery / J.Benicky, E. Sánchez-Lemus, J.
Pavel [et al.] // Cellular and Molecular Neurobiology. – 2009. –Vol. 29. – P. 781–792.363. Chronic peripheral administration of the angiotensin II AT(1) receptor antagonist candesartanblocks brain AT(1) receptors / Y. Nishimura, T. Ito, K. Hoe [et al.] // Brain Research. – 2000. –Vol. 871. – P. 29–38.364. Oral administration of an AT1 receptor antagonist prevents the central effects of angiotensin IIin spontaneously hypertensive rats / A.
Seltzer, C. Bregonzio, I. Armando [et al.] // BrainResearch. – 2004. – Vol. 1028. – P. 9–18.365. A systematic comparison of the properties of clinically used angiotensin II type 1 receptorantagonists / M.C. Michel, C. Foster, H.R. Brunner [et al.] // Pharmacological Reviews.
– 2013. –Vol. 65. – P. 809–848.366. Evaluation of direct transport pathways of glycine receptor antagonists and an angiotensinantagonist from the nasal cavity to the central nervous system in the rat model / S.T. Charlton, J.Whetstone, S.T. Fayinka [et al.] // Pharmaceutical Research. – 2008. – Vol. 25. – P. 1531–1543.367. Hawkes, C.H. Parkinson’s disease: the dual hit theory revisited / C.H.
Hawkes, K. Del Tredici,H. Braak // Annals of the New York Academy of Sciences. - 2009. – Vol. 1170. – P. 615–622.368. Obermeier, B. Development, maintenance and disruption of the blood-brain barrier / B.Obermeier, R. Daneman, R.M. Ransohoff // Nature Medicine. – 2013. – Vol. 19. – P. 1584–1596.369. Impact of angiotensin receptor blockers on Alzheimer’s disease neuropathology in a large brainautopsy series / I.
Hajjar, L. Brown, W. J. Mack [et al.] // Archives of neurology. – 2012. – Vol.69. – P. 1632–1638.370. Nation, D.A. Older adults taking AT1-receptor blockers exhibit reduced cerebral amyloidretention / D.A. Nation, J. Ho, B. Yew // Journal of Alzheimer's Disease. – 2016. – Vol. 50. – P.779–789.371. Hypertension and longitudinal changes in cerebral blood flow: The SMART‐MR study / M.Muller, Y. van der Graaf, F.L.
Visseren [et al.] // Annals of Neurology. – 2012. – Vol. 71, N 6. –P. 825-833.372. Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patientswith Alzheimer’s disease / K. Kume, H. Hanyu, H. Sakurai [et al.] // Geriatrics & GerontologyInternational. – 2012. – Vol. 12.
– P. 207–214.373. Non-hypotensive dose of telmisartan and nimodipine produced synergistic neuroprotectiveeffect in cerebral ischemic model by attenuating brain cytokine levels / A. Justin, M.170Sathishkumar, A. Sudheer [et al.] // Pharmacology Biochemistry and Behavior. – 2014. – Vol.122. – P. 61–73.374.
Strong reduction of low-density lipoprotein receptor/apolipoprotein E expressions bytelmisartan in cerebral cortex and hippocampus of stroke resistant spontaneously hypertensiverats / Y. Zhai, T. Yamashita, T. Kurata [et al.] // Journal of Stroke and Cerebrovascular Diseases.– 2014. – Vol. 23.
– P. 2350–2361.375. Kishi, T. Telmisartan protects against cognitive decline via up-regulation of brain-derivedneurotrophic factor/tropomyosin-related kinase B in hippocampus of hypertensive rats / T. Kishi,Y. Hirooka, K. Sunagawa // Journal of Cardiology. – 2012. – Vol. 60. – P. 489–494.376. Differential effects of short-term treatment with two AT1 receptor blockers on diameter of pialarterioles in SHR / S. Foulquier, F.
Dupuis, C. Perrin-Sarrado [et al.] // PLoS ONE. – 2012. - №7. – P. e42469.171ПРИЛОЖЕНИЯ.Приложение 1. Методика измерения офисного АДУровень АД измеряли при помощи механического тонометра в спокойной и удобнойобстановке, в комнате с комфортной температурой. Избегали появления внешних воздействий,которые могли увеличивать вариабельность АД пациента, и шумов, которые мешали четкослышать тоны Короткова. Использовали стандартную манжету длиной шириной 13 см и длиной35 см, манжету располагали на плече на уровне сердца.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
